A carregar...
Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report
INTRODUCTION: Febuxostat, a nonpurine xanthine oxidase inhibitor, is approved as the first-line urate-lowering therapy in gout patients with normal renal function or mild to moderate renal impairment. The most common adverse effects of febuxostat are liver function test abnormalities, diarrhea, and...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5266183/ https://ncbi.nlm.nih.gov/pubmed/28079821 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005863 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|